Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cutia Therapeutics's operating assets for the quarter that ended in Dec. 2025 was HK$572.3 Mil. Cutia Therapeutics's operating liabilities for the quarter that ended in Dec. 2025 was HK$114.5 Mil. Cutia Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was HK$1,220.1 Mil. Therefore, Cutia Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.38.
Cutia Therapeutics Scaled Net Operating Assets Related Terms
Cutia Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics Scaled Net Operating Assets Chart
HKSE:02487 vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Cutia Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.38 mean?
Cutia Therapeutics (HKSE:02487) has a Scaled Net Operating Assets of 0.38 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cutia Therapeutics and its competitors.
Is Cutia Therapeutics' Scaled Net Operating Assets too high?
Cutia Therapeutics' current Scaled Net Operating Assets is 0.38. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Scaled Net Operating Assets compare to VRTX and REGN?
Cutia Therapeutics' Scaled Net Operating Assets of 0.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cutia Therapeutics and its competitors. Cutia Therapeutics's current Scaled Net Operating Assets is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current Scaled Net Operating Assets is 0.38. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Scaled Net Operating Assets is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
Scaled Net Operating Assets: 0.38
GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score
Get the complete analysis for HKSE:02487
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
